Adamas Pharmaceuticals (Adamas Pharmaceuticals) Buyback Yield % : -17.67 (As of Jun. 07, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Adamas Pharmaceuticals's current buyback yield was -17.67%.

Adamas Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Adamas Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adamas Pharmaceuticals Buyback Yield % Chart

Adamas Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Buyback Yield %

Get a 7-Day Free Trial

-16.62

-57.31

-0.83

Adamas Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Buyback Yield %	Get a 7-Day Free Trial															-	-	-122.35	0.27	-

Competitive Comparison of Adamas Pharmaceuticals's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Adamas Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adamas Pharmaceuticals's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adamas Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Adamas Pharmaceuticals's Buyback Yield % falls into.

Adamas Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Adamas Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2020 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	1.041)	/	124.99411
	=	-0.83%

Adamas Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2021 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	224.340846
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2021) data.

Adamas Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608

Website

http://www.adamaspharma.com

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

Executives

Vijay Shreedhar	officer: Chief Commercial Officer	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss	officer: Chief Financial Officer	1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier	director	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson	director, 10 percent owner	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee	director	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg	director	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham	director	890 WINTER STREET, WALTHAM MA 02451
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane	officer: Chief Executive Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather	officer: Chief Financial Officer
Jennifer J Rhodes	officer: CBO, GC & Compliance Officer	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went	director, officer: Chief Executive Officer	C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni	officer: Chief Medical Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301